LDLR and neoplasm: By using VLDL as a carrier to encapsulate COS derivatives (such as sulfated COS), they target the high expression of LDLR on tumor cells; COS enhances tumor immunity (such as activating T cells), while VLDL provides an energy blockade (inhibiting tumor lipid uptake).